India to Begin Domestic Production of Clavulanic Acid, Key Antibiotic Ingredient, Under PLI Scheme
India to begin producing Clavulanic Acid for antibiotics, fueled by PLI scheme investment.
Dr. Arunish Chawla, Secretary of the Department of
Pharmaceuticals, announced that India is set to begin production of Clavulanic
Acid, a critical component in the antibiotic Augmentin, which treats various
bacterial infections. Speaking to ANI, Dr. Chawla shared that the Production
Linked Incentive (PLI) scheme for bulk drugs has attracted significant
investment, enabling the local manufacture of both Penicillin G and Clavulanic
Acid, which are essential for producing half of the beta-lactam antibiotics available
in the market.
Dr. Chawla highlighted that India once produced these bulk
drugs but lost ground to foreign competition. However, with the success of the
PLI scheme, India is poised to regain its footing in antibiotic production. The
new manufacturing plants are expected to be commissioned soon, marking a
significant milestone in reducing reliance on imports and strengthening India’s
pharmaceutical industry.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Tonix Plans Adaptive Phase 2 Trial for Seasonal Lyme Disease Prevention Therapy, Advances Program Following FDA Type C Meeting
Medicus Pharma Appoints Dr. Faisal Mehmud as CEO of UK Subsidiary Antev, Strengthens Leadership to Advance Global Development of Teverelix®
Discussion